AustraliaHealth

Pro Medicus (ASX:PME) announced a first-half revenue increase of 28.4% to $124.8 million, while underlying profit before tax rose nearly 30% to $90.7 million.

ECS Botanics (ASX:ECS) announced a landmark strategic partnership with Nimbus Health, a premier German distributor.

Rhythm Biosciences (ASX:RHY) has entered its commercialisation era, announcing the first physician enrollment in its ColoSTAT Access Program.

CSL (ASX:CSL) reports its H1 FY26 financial results, highlighting a resilient US$8.3 billion revenue despite a challenging landscape.

CSL (ASX:CSL) announced that Dr. Paul McKenzie will retire as CEO and Managing Director, effective immediately.

Immuron (ASX:IMC) announced a leadership transition, following the resignation of Phillip Hains as CFO and company secretary.

Algorae Pharmaceuticals (ASX:1AI) has formalised a definitive license and supply agreement with India’s Cadila Pharmaceuticals.

Memphasys (ASX:MEM) has announced that its flagship Felix System has secured official approval from the Therapeutic Goods Administration.

Atomo Diagnostics (ASX:AT1) has secured a material purchase order worth approximately $630,000 from the National Association of People with HIV Australia for the supply of HIV self-tests.

Immutep (ASX:IMM) announced a significant operational breakthrough in its global TACTI-004 (KEYNOTE-F91) Phase 3 clinical trial.

Australian biotech firm Terragen (ASX:TGH) announced binding commitments for a $7 million equity raising.

Neuren Pharmaceuticals (ASX:NEU) has commenced dosing in its "Koala" Phase 3 clinical trial.